Oncology Biosimilars Outlook: How Key Stakeholders Can Plan for Change

Posted by ZS Editors on Jul 24, 2017 1:04:28 PM

With the oncology biosimilars market poised for expansion, ZS launched an effort to survey the landscape. Our 2017 Biosimilar Adoption Study polled 252 respondents—including 200 oncologists, 25 payers and 27 pharmacy directors—and the results provide a perspective on market perceptions and other factors that could drive or restrict oncology biosimilars’ adoption. 


>
Read More